1st European CAR T Cell Meeting

1st European CAR T Cell Meeting is organized by European Hematology Association (EHA) and will be held from Feb 14 - 16, 2019 at Novotel Tour Eiffel Hotel, Paris, Ile-de-France, France.

Target audience:
The target audience is hematologists, oncologists, physicians, nurses, data managers, supply chain managers, and patient organization representatives.

EHA Topics-in-Focus Immunotherapy:
Topics in Focus Immunotherapy 4This meeting is part of the Topics-in-Focus program on Immunotherapy, launched by the EHA Board at EHA23. This program is aimed at raising awareness, providing education, furthering research, and building a network of experts with the ultimate goal to improve patient care

Course Description:
This meeting, first of its kind in Europe, is jointly organized by the European Hematology Association (EHA) and the European Society for Blood and Marrow Transplantation (EBMT).

The recent approval of the first CAR T cell treatments in Europe presents a great opportunity to fight hematological malignancies but also poses serious challenges given the peculiar nature of the treatment. Patients, physicians, nurses, hospitals and whole health systems need to learn how to select the right treatments, handle specific toxicities, organize treatment units and cope with the increasing costs connected with CAR T therapy.

This meeting provides the ideal context to meet these learning objectives, with speakers that will share first-hand experience, including presenters from the US that pioneered the field. The program will include a comprehensive outlook on the current research efforts to increase CAR T cell therapies efficacy and targets, with input from basic researchers as well as representatives from the industry.

Learning objectives:
After attending this meeting, you should be able to:
• select patients for currently approved CAR T therapies,
• recognize and manage toxicities related to CAR T therapies,
• review therapeutic areas where new CAR T therapies are being tested,
• describe the requirements for manufacturing and administering CAR T cells, and
• highlight novel targets and technologies for the next generation of CAR T.

Additional details will be posted as soon as they are available.